Cohance Life

Why is Cohance Lifesciences Ltd falling/rising?

As of 03-Aug, Cohance Lifesciences Ltd's stock price is Rs 425.00, reflecting a decline of -0.01%. The stock has underperformed significantly, with a year-to-date drop of -19.58% and a one-year decline of -56.65%, attributed to poor financial results and high promoter pledging.

As of 03-Aug, Cohance Lifesciences Ltd is experiencing a slight decline in its stock price, currently at Rs 425.00, which reflects a change of -0.05 (-0.01%). The stock has been underperforming significantly in both the short and long term, with a consecutive fall over the last three days resulting in a total decline of -2.19%. <BR><BR>In the past week, the stock has decreased by -1.12%, while the benchmark Sensex has increased by +2.35%. Over the past month, the stock has fallen by -6.56%, contrasting with a +1.13% rise in the Sensex. Year-to-date, the stock is down -19.58%, compared to a -7.72% decline in the benchmark. The one-year performance is particularly concerning, with the stock down -56.65% while the Sensex has only decreased by -2.43%. <BR><BR>The company's financial health is also a contributing factor to the stock's decline. It has reported negative results for the last three consecutive quarters, with a significant drop in net sales of -0.54% and a staggering -76.62% decline in profit after tax over the latest six months. The return on equity is low at 5, and the stock is trading at a premium compared to its peers, with a price-to-book value of 4.1. Additionally, a high percentage of promoter shares, 94.56%, are pledged, which can exert further downward pressure on the stock price in a falling market.<BR><BR>Overall, the combination of poor financial performance, negative growth trends, and high promoter pledging is leading to the stock's decline.

Which are the latest news on Cohance Life?

What does Cohance Life do?

Cohance Lifesciences Ltd is a CDMO in the Pharmaceuticals & Biotechnology sector, incorporated in 2018 and formerly known as Suven Pharmaceuticals. As of March 2026, it reported net sales of 619 Cr and a net profit of 20 Cr, with a market cap of INR 16,804 Cr.

Overview:<BR>Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company operating in the Pharmaceuticals & Biotechnology industry within the Small Cap market-cap bracket.<BR><BR>History:<BR>Cohance Lifesciences Ltd was incorporated on November 6, 2018, and was formerly known as Suven Pharmaceuticals Limited. The company changed its name to Cohance Lifesciences Limited effective May 7, 2025. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 619 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 20 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 16,804 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 84.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.02 <BR>Return on Equity: 5.00% <BR>Price to Book: 4.23 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is Cohance Life?

As of 10th June, Cohance Lifesciences Ltd has a market capitalization of 16,804.00 Cr, with recent net sales of 2,268.55 Cr and a net profit of 179.23 Cr. The company reported shareholder's funds of 1,696.58 Cr and total assets of 3,031.20 Cr for the latest annual period ending in March 2025.

As of 10th June, Cohance Lifesciences Ltd has a market capitalization of 16,804.00 Cr, classifying it as a Small Cap company.<BR><BR>In the latest four quarters, Cohance Lifesciences Ltd reported Net Sales of 2,268.55 Cr and a Net Profit of 179.23 Cr.<BR><BR>For the latest annual period ending in March 2025, the company had Shareholder's Funds amounting to 1,696.58 Cr and Total Assets of 3,031.20 Cr.

Who are in the management team of Cohance Life?

The management team of Cohance Life includes Venkateswarlu Jasti (Managing Director), J V Ramudu (Chairman & Non-Executive Director), and several independent and non-executive directors, playing key roles in the company's governance and strategy.

The management team of Cohance Life includes the following individuals:<BR><BR>1. **Venkateswarlu Jasti** - Managing Director<BR>2. **Deepanwita Chattopadhyay** - Independent Director<BR>3. **V Sambasiva Rao** - Independent Director<BR>4. **Jerry Jeyasingh** - Non-Executive & Non-Independent Director<BR>5. **Hanumantha Rao Kokkonda** - Company Secretary<BR>6. **D G Prasad** - Independent Director<BR>7. **J V Ramudu** - Chairman & Non-Executive Director<BR>8. **Shweta Jalan** - Non-Executive Director<BR>9. **U B Pravin Rao** - Independent Director<BR><BR>This team plays a crucial role in the governance and strategic direction of the company.

Who are the peers of the Cohance Life?

Cohance Life's peers include ERIS Lifescience, OneSource Speci., Granules India, Caplin Point Lab, Natco Pharma, Jubilant Pharmo, Alembic Pharma, Concord Biotech, and Alivus Life. Cohance Life has average management risk, below-average growth, and the lowest 1-year return at -57.78% among its peers.

Peers: The peers of Cohance Life are ERIS Lifescience, OneSource Speci., Granules India, Caplin Point Lab, Natco Pharma, Jubilant Pharmo, Alembic Pharma, Concord Biotech, and Alivus Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at ERIS Lifescience, Granules India, Caplin Point Lab, Natco Pharma, Alembic Pharma, Concord Biotech, and Alivus Life, while Average management risk is found at Cohance Life and Jubilant Pharmo. Below Average management risk is noted for OneSource Speci. Growth is Excellent at OneSource Speci., while Below Average growth is seen at ERIS Lifescience, Granules India, Caplin Point Lab, Cohance Life, Natco Pharma, Jubilant Pharmo, Alembic Pharma, Concord Biotech, and Alivus Life. The Capital Structure is Excellent for Granules India, Caplin Point Lab, Cohance Life, Natco Pharma, Alembic Pharma, Concord Biotech, and Alivus Life, while Good capital structure is noted for ERIS Lifescience, and Below Average for OneSource Speci.<BR><BR>Return Snapshot: Granules India has the highest 1-year return at 44.86%, while Cohance Life has the lowest at -57.78%. Cohance Life's return is significantly lower than all peers. Additionally, the six-month return is negative for ERIS Lifescience, OneSource Speci., Cohance Life, Natco Pharma, Jubilant Pharmo, Alembic Pharma, and Concord Biotech.

Are Cohance Lifesciences Ltd latest results good or bad?

Cohance Lifesciences Ltd's latest results are concerning, showing an 83.77% decline in net profit and a 26.33% drop in net sales year-on-year, alongside significant margin compression and a high tax rate. Overall, these metrics indicate serious operational challenges for the company.

Cohance Lifesciences Ltd's latest results indicate a troubling performance. In Q4 FY26, the company reported a consolidated net profit of ₹19.55 crores, which represents a significant decline of 83.77% year-on-year. Additionally, net sales fell by 26.33% to ₹619.12 crores, marking the fourth consecutive quarter of negative year-on-year growth.<BR><BR>Operating margins also saw a sharp contraction, dropping from 27.27% in the previous year to just 15.94%. This decline in profitability was further compounded by an unusually high tax rate of 58.26%, which is well above the company's historical average.<BR><BR>While there was a slight sequential improvement in sales, with a 13.69% increase from the previous quarter, the overall financial metrics reflect a serious crisis in profitability. The company's return on equity has also declined significantly, indicating deteriorating capital efficiency.<BR><BR>In summary, the latest results for Cohance Lifesciences are concerning, with substantial declines in both profit and sales, alongside significant margin compression. This suggests that the company is facing considerable operational challenges.

Should I buy, sell or hold Cohance Lifesciences Ltd?

When is the next results date for Cohance Lifesciences Ltd?

Cohance Lifesciences Ltd will announce its results on 12 May 2026.

Cohance Lifesciences Ltd is scheduled to declare its results on 12 May 2026.

How has been the historical performance of Cohance Life?

Cohance Life has demonstrated significant growth, with net sales rising to 2,608.50 Cr in March 2025 from 1,051.35 Cr in March 2024, and profit after tax increasing to 484.24 Cr. Despite a decline in operating profit margin, the company shows strong operational performance and a robust financial trajectory.

Answer:<BR>Cohance Life has shown significant growth in its historical performance, particularly in net sales and profit metrics. <BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Cohance Life reported net sales of 2,608.50 Cr, a substantial increase from 1,051.35 Cr in March 2024 and 1,340.33 Cr in March 2023. The total operating income mirrored this growth, reaching 2,608.50 Cr in March 2025, compared to 1,051.35 Cr in the previous year. The company's total expenditure also rose to 1,811.44 Cr in March 2025 from 645.54 Cr in March 2024, primarily driven by increased raw material costs and employee expenses. Operating profit (PBDIT) for March 2025 was reported at 866.27 Cr, up from 467.72 Cr in March 2024, indicating a strong operational performance despite a decline in operating profit margin to 30.56% from 38.6%. Profit before tax increased to 642.63 Cr in March 2025, while profit after tax reached 484.24 Cr, reflecting a growth from 300.28 Cr in March 2024. The company's total assets grew to 3,031.20 Cr in March 2025, up from 2,254.09 Cr in March 2024, with total liabilities also increasing to 3,031.20 Cr. Cash flow from operating activities was 288.00 Cr in March 2025, down from 358.00 Cr in March 2024, but the company ended with a net cash inflow of 38.00 Cr, compared to a net outflow of 17.00 Cr in the previous year. Overall, Cohance Life's financial trajectory indicates robust growth and operational scaling over the years.

Is Cohance Life technically bullish or bearish?

As of October 27, 2025, Cohance Life's technical trend has shifted to a moderate bearish stance, supported by bearish indicators across MACD, Bollinger Bands, and moving averages, alongside a significant 1-year decline of -31.85%.

As of 27 October 2025, the technical trend for Cohance Life has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this conclusion include a bearish MACD on the weekly chart, bearish Bollinger Bands on both weekly and monthly time frames, and a bearish moving average on the daily chart. Additionally, the Dow Theory indicates a mildly bearish trend on both weekly and monthly levels. The stock's recent performance shows a significant decline, with a 1-year return of -31.85%, further supporting the bearish outlook.

Who are the top shareholders of the Cohance Life?

The top shareholders of Cohance Life include Berhyanda Limited with 33.34%, mutual funds with 8.65%, foreign institutional investors at 7.38%, Jasti Property And Equity Holdings Private Limited with 6.59%, and individual investors holding 6.63%.

The top shareholders of Cohance Life include several key players. The majority shareholder is Berhyanda Limited, which holds a significant 33.34% of the company. Additionally, mutual funds collectively hold 8.65% through 28 schemes, while foreign institutional investors (FIIs) account for 7.38% with 167 different FIIs involved. The highest public shareholder is Jasti Property And Equity Holdings Private Limited, with a stake of 6.59%. Individual investors also have a notable presence, holding 6.63% of the shares.

Is Cohance Life overvalued or undervalued?

As of November 9, 2022, Cohance Life is considered overvalued with a high PE ratio of 100.54 and an EV to EBITDA of 71.77, despite similar metrics to its peer Suven Pharmaceuticals, and its recent performance has declined by -9.38% year-to-date compared to the Sensex's 5.56% gain.

As of 9 November 2022, Cohance Life has moved from expensive to very expensive, indicating a significant shift in valuation perception. The company is currently overvalued, as evidenced by its high PE ratio of 100.54, an EV to EBITDA ratio of 71.77, and a Price to Book Value of 15.87. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peer, Suven Pharmaceuticals Ltd., which has a similar PE ratio of 100.54 and an EV to EBITDA of 71.77, Cohance Life's valuation appears excessive. The company's return metrics, with a ROCE of 17.56% and ROE of 15.79%, do not justify such high valuation multiples. Furthermore, while the stock has outperformed the Sensex over the long term, recent performance shows a decline, with a year-to-date return of -9.38% compared to the Sensex's 5.56%. This reinforces the view that the stock is overvalued in the current market context.

What is the bonus history of the Cohance Life?

Cohance Life issued a 1:1 bonus on September 25, 2020, with a record date of September 28, 2020, allowing shareholders to double their holdings by receiving an additional share for each share owned.

Cohance Life has a bonus history that includes a 1:1 bonus issue announced on September 25, 2020. The record date for this bonus was September 28, 2020. This means that for every share held, shareholders received an additional share, effectively doubling their holdings at that time.

Has Cohance Life declared dividend?

Cohance Lifesciences Ltd has declared a 100% dividend, amounting to 5 per share, but the dividend yield is 0%. While the company has shown significant price appreciation over various periods, it has not consistently provided dividend returns.

Cohance Lifesciences Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 5<BR>- Ex-date: 09 Sep 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -19.08%, with a dividend return of 0%, resulting in a total return of -19.08%.<BR><BR>Over the past year, the price return was 66.12%, with a dividend return of 0%, leading to a total return of 66.12%.<BR><BR>In the last 2 years, the price return was 122.25%, with a dividend return of 0%, resulting in a total return of 122.25%.<BR><BR>For the 3-year period, the price return was 115.92%, with a dividend return of 1.09%, culminating in a total return of 117.01%.<BR><BR>In the 4-year period, the price return was 103.18%, with a dividend return of 1.90%, leading to a total return of 105.08%.<BR><BR>Over the last 5 years, the price return was 539.98%, with a dividend return of 0%, resulting in a total return of 539.98%.<BR><BR>Overall, while Cohance Lifesciences Ltd has declared a dividend, the dividend yield remains at 0%. The total returns over various periods indicate significant price appreciation, particularly over the longer term, despite the lack of consistent dividend returns.